NASDAQ:ZYNEZynerba Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.15 -0.03 (-0.72 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$4.08Now: $4.15▼$4.3550-Day Range$3.25MA: $4.32▼$6.5452-Week Range$2.55Now: $4.15▼$12.51Volume781,020 shsAverage Volume1.11 million shsMarket Capitalization$103.55 millionP/E RatioN/ADividend YieldN/ABeta3.07 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingZynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.86, Zynerba Pharmaceuticals has a potential upside of 233.9% from its current price of $4.15.Amount of Analyst CoverageZynerba Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesZynerba Pharmaceuticals has received 626 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZynerba Pharmaceuticals has received 553 “underperform” votes. (Add your “underperform” vote.)Community SentimentZynerba Pharmaceuticals has received 53.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote “Outperform” if you believe ZYNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZynerba Pharmaceuticals does not currently pay a dividend.Dividend GrowthZynerba Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynerba Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.10% of the stock of Zynerba Pharmaceuticals is held by insiders.Percentage Held by Institutions36.63% of the stock of Zynerba Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($1.77) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynerba Pharmaceuticals is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynerba Pharmaceuticals is -2.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZynerba Pharmaceuticals has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.74 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYNE Previous Symbol CUSIPN/A CIK1621443 Webwww.zynerba.com Phone484-581-7505Debt Debt-to-Equity RatioN/A Current Ratio7.31 Quick Ratio7.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90,000.00 Price / Sales1,150.52 Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book1.27Profitability EPS (Most Recent Fiscal Year)($1.50) Net Income$-32,940,000.00 Net MarginsN/A Return on Equity-46.27% Return on Assets-40.82%Miscellaneous Employees25 Outstanding Shares24,951,000Market Cap$103.55 million Next Earnings DateN/A OptionableOptionable $4.15 -0.03 (-0.72 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ZYNE News and Ratings via Email Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter. Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions How has Zynerba Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZYNE stock has increased by 6.7% and is now trading at $4.15. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Zynerba Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zynerba Pharmaceuticals. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.03. View Zynerba Pharmaceuticals' earnings history. What price target have analysts set for ZYNE? 7 brokers have issued twelve-month price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.00 to $26.00. On average, they expect Zynerba Pharmaceuticals' stock price to reach $13.86 in the next year. This suggests a possible upside of 233.9% from the stock's current price. View analysts' price targets for Zynerba Pharmaceuticals. What are Wall Street analysts saying about Zynerba Pharmaceuticals stock? Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock: 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (5/30/2020) 2. LADENBURG THALM/SH SH analysts commented, "We understand the market’s reaction when focusing on a few items: 1) There was a case of status epilepticus (SE); 2) 96% of patients reported an adverse event (AE); 3) 10/48 (21%) reported a serious adverse event (SAE); 4) Zygel doesn’t work fast enough; 5) 7 of 48 (15%) dropped out for efficacy; and 6) There were only 11 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) patients. However, we find some perspective on these figures are important to consider: 1. SE has not been found in any previous Zygel trial, including the Phase 2s in adult refractory epilepsy (n=188), osteoarthritis of the knee (n=300) and Fragile X syndrome (FXS; n=16). As we have described in our notes on Buy), SE typically occurs in patients highly compromised by underlying health conditions and/or trauma." (9/18/2019) Has Zynerba Pharmaceuticals been receiving favorable news coverage? Media headlines about ZYNE stock have trended neutral recently, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Zynerba Pharmaceuticals. Who are some of Zynerba Pharmaceuticals' key competitors? Some companies that are related to Zynerba Pharmaceuticals include Xenon Pharmaceuticals (XENE), Avedro (AVDR), Kamada (KMDA), MannKind (MNKD), Neoleukin Therapeutics (NLTX), Organogenesis (ORGO), Amryt Pharma (AMYT), Satsuma Pharmaceuticals (STSA), Merus (MRUS), Ovid Therapeutics (OVID), Atreca (BCEL), ANI Pharmaceuticals (ANIP), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Albireo Pharma (ALBO). View all competitors. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Insys Therapeutics (INSY), Advanced Micro Devices (AMD) and Innovative Industrial Properties (IIPR). Who are Zynerba Pharmaceuticals' key executives? Zynerba Pharmaceuticals' management team includes the following people: Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)Ms. Terri B. Sebree, Pres (Age 61)Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62) When did Zynerba Pharmaceuticals IPO? (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What is Zynerba Pharmaceuticals' stock symbol? Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE." Who are Zynerba Pharmaceuticals' major shareholders? Zynerba Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Zeke Capital Advisors LLC (1.77%), AdvisorShares Investments LLC (1.53%), Nisa Investment Advisors LLC (0.08%) and Davy Global Fund Management Ltd (0.05%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler and Terri B Sebree. View institutional ownership trends for Zynerba Pharmaceuticals. Which institutional investors are buying Zynerba Pharmaceuticals stock? ZYNE stock was purchased by a variety of institutional investors in the last quarter, including Zeke Capital Advisors LLC, AdvisorShares Investments LLC, Nisa Investment Advisors LLC, and Davy Global Fund Management Ltd. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, and Terri B Sebree. View insider buying and selling activity for Zynerba Pharmaceuticals. How do I buy shares of Zynerba Pharmaceuticals? Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zynerba Pharmaceuticals' stock price today? One share of ZYNE stock can currently be purchased for approximately $4.15. How big of a company is Zynerba Pharmaceuticals? Zynerba Pharmaceuticals has a market capitalization of $103.55 million and generates $90,000.00 in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe. What is Zynerba Pharmaceuticals' official website? The official website for Zynerba Pharmaceuticals is www.zynerba.com. How can I contact Zynerba Pharmaceuticals? Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
